DexCom Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

DexCom wird ein jährliches Gewinn- und Umsatzwachstum von 18.2% bzw. 14.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 16.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 30.8% betragen.

Wichtige Informationen

18.2%

Wachstumsrate der Gewinne

16.6%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.6%
Wachstumsrate der Einnahmen	14.9%
Zukünftige Eigenkapitalrendite	30.8%
Analystenabdeckung	Good
Zuletzt aktualisiert	24 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

BOVESPA:D1EX34 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	6,048	1,137	1,140	1,573	17
12/31/2025	5,152	908	878	1,260	23
12/31/2024	4,330	729	673	1,082	23
3/31/2024	3,802	639	584	802	N/A
12/31/2023	3,622	542	512	749	N/A
9/30/2023	3,403	377	500	747	N/A
6/30/2023	3,198	358	466	771	N/A
3/31/2023	3,023	293	416	754	N/A
12/31/2022	2,910	341	305	670	N/A
9/30/2022	2,793	244	261	643	N/A
6/30/2022	2,673	230	216	597	N/A
3/31/2022	2,572	258	95	486	N/A
12/31/2021	2,449	217	53	443	N/A
9/30/2021	2,319	577	140	509	N/A
6/30/2021	2,170	562	101	409	N/A
3/31/2021	2,027	530	236	502	N/A
12/31/2020	1,927	550	277	476	N/A
9/30/2020	1,821	231	264	447	N/A
6/30/2020	1,716	205	209	394	N/A
3/31/2020	1,601	148	131	305	N/A
12/31/2019	1,476	101	135	315	N/A
9/30/2019	1,351	-171	51	205	N/A
6/30/2019	1,222	-170	39	167	N/A
3/31/2019	1,128	-130	53	144	N/A
12/31/2018	1,032	-127	56	123	N/A
9/30/2018	915	43	64	131	N/A
6/30/2018	833	-5	53	110	N/A
3/31/2018	761	-33	25	83	N/A
12/31/2017	719	-50	N/A	92	N/A
9/30/2017	669	-48	N/A	64	N/A
6/30/2017	633	-65	N/A	51	N/A
3/31/2017	599	-88	N/A	57	N/A
12/31/2016	573	-66	N/A	56	N/A
9/30/2016	533	-57	N/A	54	N/A
6/30/2016	490	-80	N/A	49	N/A
3/31/2016	445	-64	N/A	45	N/A
12/31/2015	402	-58	N/A	49	N/A
9/30/2015	356	-58	N/A	46	N/A
6/30/2015	319	-20	N/A	40	N/A
3/31/2015	285	-23	N/A	29	N/A
12/31/2014	259	-22	N/A	24	N/A
9/30/2014	227	-26	N/A	20	N/A
6/30/2014	201	-27	N/A	10	N/A
3/31/2014	178	-31	N/A	5	N/A
12/31/2013	160	-30	N/A	2	N/A
9/30/2013	142	-36	N/A	-13	N/A
6/30/2013	122	-47	N/A	-20	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: D1EX34Das prognostizierte Gewinnwachstum (18.2% pro Jahr) liegt über der Sparquote (9.9%).

Ertrag vs. Markt: D1EX34Die Erträge des Unternehmens (18.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt BR (14% pro Jahr).

Hohe Wachstumserträge: D1EX34Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: D1EX34Die Einnahmen des Unternehmens (14.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt BR (7.2% pro Jahr).

Hohe Wachstumseinnahmen: D1EX34Die Einnahmen des Unternehmens (14.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: D1EX34Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (30.8%)

DexCom Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

DexCom, Inc. Provides Earnings Guidance for the Year 2024

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2024

Dexcom, Inc. Provides Revenue Guidance for the Full Year of 2024

DexCom, Inc. Increases Earnings Guidance for the Fiscal Year 2023

DexCom, Inc. Updates Earnings Guidance for the Year 2025

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2023

Recent updates

Dexcom Showcases Extensive Clinical Data At ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People with Type 2 Diabetes

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects Directly to Apple Watch in the United States

Dexcom Wins Access to Dexcom One for 100,000 People Living with Type 2 Diabetes

DexCom, Inc. Provides Earnings Guidance for the Year 2024

DexCom, Inc., Annual General Meeting, May 22, 2024

DexCom, Inc., Annual General Meeting, May 22, 2024

DexCom, Inc. to Report Q1, 2024 Results on Apr 25, 2024

DexCom, Inc. Announces the FDA Clears Stelo by Dexcom – the First Glucose Biosensor

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2024

DexCom, Inc. Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the t:Slim X2™ Insulin Pump by Tandem Diabetes Care in Countries Across Europe and in South Africa

DexCom, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Dexcom, Inc. Provides Revenue Guidance for the Full Year of 2024

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the Tandem t:slim X2 Insulin Pump

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $500 million worth of its shares.

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring with New Clinical Data Presented at EASD

DexCom, Inc. to Report Q3, 2023 Results on Oct 26, 2023

DexCom, Inc Announces the Availability of Its Dexcom One Real-Time CGM Sensor Via Reimbursement, in France

DexCom, Inc. Announces Appointment of Rimma Driscoll to Its Board of Directors

DexCom, Inc. Increases Earnings Guidance for the Fiscal Year 2023

DexCom, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Dexcom, Inc. Receives Health Canada Approval: Next-Generation Continuous Glucose Monitoring System with Unmatched Accuracy Coming to Canadians

DexCom, Inc. Updates Earnings Guidance for the Year 2025

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2023

Dexcom, Inc.'s G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program

DexCom, Inc. to Report Q4, 2022 Results on Feb 09, 2023

Dexcom, Inc. Receives FDA Clearance of Next-Generation Dexcom G7 Continuous Glucose Monitoring System

DexCom, Inc. Provides Earnings Guidance for the Year 2022

DexCom, Inc. Announces the Launch of Dexcom U

DexCom, Inc. Announces Launch of Dexcom G7 in the United Kingdom, Ireland, Germany, Austria and Hong Kong – Initiating Global Rollout of World’s Most Powerful Continuous Glucose Monitoring System

DexCom, Inc. to Report Q3, 2022 Results on Oct 27, 2022

DexCom, Inc. Promotes Jacob S. Leach to Chief Operating Officer

DexCom, Inc. Announces One Real-Time Continuous Glucose Monitoring (rt-CGM) System Available on Prescription in the UK

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $700 million worth of its shares.

DexCom, Inc. Revises Earnings Guidance for the Full Year 2022

DexCom, Inc. Announces Resignation of Chad M. Patterson as Executive Vice President, Global Marketing, Effective July 15, 2022

DexCom, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Dexcom Says Not in Active Merger Talks

Dexcom Reportedly in Talks to Acquire Insulet

DexCom, Inc. Showcases Expanded CGM Portfolio at International ATTD Conference

Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices

DexCom, Inc. to Report Q1, 2022 Results on Apr 28, 2022

DexCom, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022

Dexcom, Inc. Reports Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Fiscal Year Ended December 31, 2021; Revenue Guidance for the Fiscal Year 2022

Dexcom G6 Continuous Glucose Monitoring System Now Covered in Manitoba for Young People with Type 1 Diabetes

Dexcom, Inc. Announces Non-insured Health Benefits Program Covers Dexcom G6 Continuous Glucose Monitoring System for Children and Adolescents on Intensive Insulin Therapy

FDA Clears DexCom, Inc.'s Real-Time APIs for Third-Party Apps and Devices

DexCom, Inc.(NasdaqGS:DXCM) dropped from Russell Top 200 Index

DexCom, Inc. Announces Results of Two New Studies Illustrate Continued Momentum for Dexcom CGM, Including JAMA-Published Data on Additional Populations Who Can Benefit from the Technology

DexCom, Inc. (NasdaqGS:DXCM) acquired assets in the Netherlands, Belgium and Luxembourg from a Dexcom distributor.

DexCom, Inc. Increasing Revenue Guidance for Fiscal Year 2021

DexCom, Inc. Announces Launch of Dexcom Ventures

Everside Health's Legacy Healthstat Partners with Dexcom to Provide Continuous Glucose Monitoring for Type 2 Diabetes

DexCom, Inc. to Report Q4, 2020 Results on Feb 11, 2021

DexCom, Inc. Revises Revenue Guidance for Fiscal Year 2020

DexCom Announces Retirement of Rick Doubleday as Executive Vice President and Chief Commercial Officer

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken